MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature
出版年份 2022 全文链接
标题
MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature
作者
关键词
-
出版物
Biomedicines
Volume 10, Issue 11, Pages 2793
出版商
MDPI AG
发表日期
2022-11-03
DOI
10.3390/biomedicines10112793
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Small molecules as kinetoplastid specific proteasome inhibitors for leishmaniasis: a patent review from 1998 to 2021
- (2022) Mohd Imran et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Development of Therapeutic and Prophylactic Zinc Compositions for Use against COVID-19: A Glimpse of the Trends, Inventions, and Patents
- (2022) Mohd Imran et al. Nutrients
- The Therapeutic and Prophylactic Potential of Quercetin against COVID-19: An Outlook on the Clinical Studies, Inventive Compositions, and Patent Literature
- (2022) Mohd Imran et al. Antioxidants
- An insight into the discovery, clinical studies, compositions, and patents of macozinone: A drug targeting the DprE1 enzyme of Mycobacterium tuberculosis
- (2022) Mohd. Imran et al. Journal of Infection and Public Health
- Synthetic molecules as DprE1 inhibitors: A patent review
- (2021) Mohd. Imran et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Mycobacterial Membrane Protein Large 3 (MmpL3) Inhibitors: A Promising Approach to Combat Tuberculosis
- (2021) Mohit D. Umare et al. ChemMedChem
- Structures of the mycobacterial membrane protein MmpL3 reveal its mechanism of lipid transport
- (2021) Chih-Chia Su et al. PLOS BIOLOGY
- Structure, In Vivo Detection, and Antibacterial Activity of Metabolites of SQ109, an Anti-Infective Drug Candidate
- (2021) Satish R. Malwal et al. ACS Infectious Diseases
- Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades
- (2021) Mohd. Imran et al. Pharmaceuticals
- Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions
- (2021) Mohd Imran et al. Biomedicines
- Mycobacterium tuberculosis Pathogenesis, Infection Prevention and Treatment
- (2020) Riccardo Miggiano et al. Pathogens
- Targeting MmpL3 for anti-tuberculosis drug development
- (2020) Jani R. Bolla BIOCHEMICAL SOCIETY TRANSACTIONS
- MmpL3 inhibitors as antituberculosis drugs
- (2020) Min Shao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation based on their Docking or Crystallographic Analyses against M. tuberculosis Enzyme Targets
- (2020) Rishita Dey et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- MmpL3 Inhibition: A New Approach to Treat Nontuberculous Mycobacterial Infections
- (2020) Jigar P. Sethiya et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Mycobacterial enzyme targets and their inhibitors
- (2019) Anil Kumar Saxena et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- MmpL3 is a lipid transporter that binds trehalose monomycolate and phosphatidylethanolamine
- (2019) Chih-Chia Su et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An overview of new antitubercular drugs, drug candidates, and their targets
- (2019) Aparna Bahuguna et al. MEDICINAL RESEARCH REVIEWS
- Drug discovery in tuberculosis. New drug targets and antimycobacterial agents
- (2018) André Campaniço et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Laboratory diagnosis of tuberculosis: Advances in technology and drug susceptibility testing
- (2017) Seema Oommen et al. Indian Journal of Medical Microbiology
- High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
- (2017) Martin J Boeree et al. LANCET INFECTIOUS DISEASES
- MmpL3 is the flippase for mycolic acids in mycobacteria
- (2017) Zhujun Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Challenge of Latent TB Infection
- (2016) Henry M. Blumberg et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives
- (2016) Adrian Rendon et al. Journal of Thoracic Disease
- Structure–Function Profile of MmpL3, the Essential Mycolic Acid Transporter from Mycobacterium tuberculosis
- (2016) Juan Manuel Belardinelli et al. ACS Infectious Diseases
- Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients
- (2015) Norbert Heinrich et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Simultaneous staining of sputum smears for acid-fast and lipid-containing Myobacterium tuberculosis can enhance the clinical evaluation of antituberculosis treatments
- (2015) Xavier A. Kayigire et al. TUBERCULOSIS
- Tuberculosis Vaccines and Prevention of Infection
- (2014) Thomas R. Hawn et al. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS
- MmpL3 a potential new target for development of novel anti-tuberculosis drugs
- (2013) Geetha Vani Rayasam EXPERT OPINION ON THERAPEUTIC TARGETS
- Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action
- (2012) Katherine A Sacksteder et al. Future Microbiology
- Giving TB wheels: Public transportation as a risk factor for tuberculosis transmission
- (2011) Marsha L. Feske et al. TUBERCULOSIS
- New drugs and regimens for treatment of TB
- (2010) Eric Leibert et al. Expert Review of Anti-Infective Therapy
- SQ109
- (2008) TUBERCULOSIS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started